Skip to content
Review

[LDL-c and residual cardiovascular risk in patients with coronary artery disease].

Oct 2026 · Annales de cardiologie et d'angeiologie · 0 citations · 41 references
Medicine

TL;DR

Although the expanding therapeutic armamentarium allows for increased substantial LDL-c reductions, this has not translated into a corresponding improvement in target attainment and the underlying reasons are complex and multifactorial.

Abstract

In secondary prevention, current therapeutic management of dyslipidemia primarily aims to reduce low-density lipoprotein cholesterol (LDL-c) levels, as LDL-c is a major driver of atherosclerosis. Elevated LDL-c levels are also one of the main modifiable cardiovascular risk factors. LDL-c lowering is directly, proportionally, and linearly associated with a reduction in cardiovascular events, with no apparent threshold effect. However, patients with chronic coronary syndrome or those who have recently experienced an acute coronary event are still generally undertreated and achieve guideline-recommended targets in only one out of four cases. This article aims to explore the underlying causes of and potential solutions to this therapeutic gap, which is associated with an increased risk of cardiovascular morbidity and mortality. Treatment adherence varies considerably across studies (randomized controlled trials or real-life studies), as well as across geographical settings, and appears to be approximately 60%. However, non-adherence to treatment alone does not explain the low proportion of patients achieving LDL-c treatment targets, which remains at approximately 25%. The underlying reasons are complex and multifactorial. Paradoxically, although the expanding therapeutic armamentarium allows for increased substantial LDL-c reductions, this has not translated into a corresponding improvement in target attainment. Therapeutic inertia may arise at the patient, physician, and healthcare system levels. Furthermore, patient education and the therapeutic alliance should remain central to patient management and should be regularly reinforced and individualized.

View source

Similar papers

Review Nov 2026

[From guidelines: cardiovascular risk stratification and therapeutic targets].

The linear relationship between LDL cholesterol (LDL-C) concentrations and cardiovascular risk, together with evidence of clinical benefit associated with intensive and sustained LDL-C reduction, underlies the "the lower, the better" paradigm. Cardiovascular risk stratification is the prerequisite for defining treatmen...

F. Colivicchi, E. Manzato, S. D. Di Fusco et al. · 0 citations
Open access Oct 2026

Lipoprotein(a): a potential target for the reduction of residual cardiovascular risk in patients with chronic kidney disease

Epidemiological evidence demonstrates that atherosclerotic cardiovascular disease (ASCVD) is a major cause of death and disability in patients with chronic kidney disease (CKD). From the early stages of CKD, and in addition to specifically related conditions, the coexistence of traditional risk factors contributes to a...

L. Sechi, Luca Bulfone, A. Vacca et al. · 0 citations
Open access Oct 2026

Apolipoprotein B beyond LDL-cholesterol in predicting Atherosclerotic Cardiovascular Disease risk in high-risk populations

Despite achieving target low-density lipoprotein cholesterol (LDL-C) levels, many individuals remain at elevated atherosclerotic cardiovascular disease (ASCVD) risk. Apolipoprotein B (ApoB), reflecting atherogenic particle number instead of cholesterol mass, may better capture this residual risk. To invest...

S. Demeester, A. Misra, S. Haidermota et al. · 0 citations
Review Nov 2026

[Role of statin/ezetimibe fixed-dose combination in lipid risk management in the cardiovascular disease continuum].

The fixed-dose statin/ezetimibe combination represents an effective, simple, and generally well-tolerated therapeutic strategy to optimize lipid control in patients requiring pronounced LDL-C reductions.

A. Catapano, E. Manzato, S. D. Di Fusco et al. · 0 citations
Open access Oct 2026

Lipoprotein(a) levels in patients hospitalized for acute coronary syndrome according to prior statin therapy

The observed association between elevated Lp(a) levels and statin use is primarily driven by confounding by indication, reflecting the patients' higher baseline risk profile rather than a direct biological effect of the medication.

A. M. Hernandez, F. Santiago, J. M. Andreu Cayuelas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.